Skip to main content
. 2023 Nov 21;10:2083–2099. doi: 10.2147/JHC.S436962

Table 4.

Immunotherapy Combined with Targeted Therapy for HCC

Drugs Phase Participants ClinicalTrials.gov Start Date Status Reference
Camrelizumab + Apatinib II 20 NCT04297202 December 1, 2019 Recruiting [143]
Cabozantinib + Atezolizumab III 740 NCT03755791 June 10, 2018 Active, not recruiting [144]
Regorafenib + Pembrolizumab I 58 NCT03347292 June 18, 2018 Completed
Regorafenib + Avelumab I/II 482 NCT03475953 May 4, 2018 Recruiting [145]
Cabozantinib + Nivolumab I 15 NCT03299946 May 14, 2018 Completed [146]
Cabozantinib + Durvalumab I/II 117 NCT03539822 October 22, 2018 Active, not recruiting
Ramucirumab + Durvalumab I 85 NCT02572687 February 19, 2016 Completed
Bevacizumab + Erlotinib II 45 NCT01180959 April 14, 2011 Completed [147]
Sorafenib + Nivolumab II 24 NCT03439891 April 16, 2018 Active, not recruiting
Tivozanib + Durvalumab I/II 42 NCT03970616 September 30, 2019 Terminated [148]
Tislelizumab + Lenvatinib II 30 NCT04834986 April 30, 2021 Not yet recruiting
Camrelizumab + Apatinib II 40 NCT04826406 February 3, 2021 Recruiting
Atezolizumab + Bevacizumab III 668 NCT04102098 December 31, 2019 Active, not recruiting [149]
Durvalumab + Tremelimumab III 1324 NCT03298451 October 11,2017 Active, not recruiting [150]
Donafenib + Sintilimab II 30 NCT05162352 December 4, 2021 Recruiting
Camrelizumab + Apatinib III 674 NCT04639180 April 1, 2021 Not recruiting